Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00226785
Status:
TERMINATED
Last Update Posted:
2006-11-14
First Post:
2005-09-23
Brief Title:
Dexmedetomidine for Continuous Sedation
Sponsor:
Orion Corporation Orion Pharma
Organization:
Orion Corporation Orion Pharma
Study Overview
Official Title:
A Prospective Multi-Centre Randomised Double-Blind Comparison of Intravenous Dexmedetomidine With PropofolMidazolam for Continuous Sedation 24 Hours to 14 Days of Ventilated Patients in Intensive Care Unit
Status:
TERMINATED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to demonstrate that dexmedetomidine is non-inferior to current best practice sedation with propofolmidazolam and daily sedation stops in maintaining a target depth of sedation in long-stay intensive care unit ICU patients and that dexmedetomidine compared with current best practice reduces the length of ICU stay
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None